CooperVision’s Generation Sight initiative expands its reach for myopia management treatment

News
Article

The expansion includes community health centers in the greater Boston area and Rhode Island.

Child undergoing eye exam Image credit: AdobeStock/AlexisS/peopleimages.com

New participating centers include Charles River Community Health, The Dimock Center, DotHouse Health, Lynn Community Health Center, Providence Community Health Centers, and South Boston Community Health Center. Image credit: AdobeStock/AlexisS/peopleimages.com

A year after its launch, CooperVision’s Generation Sight initiative is expanding its reach into additional community health centers to help bridge disparities in myopia management access.1 The expansion includes health centers in the greater Boston area and Rhode Island to reach more underresourced children in the US, according to a news release.

“The expansion of Generation Sight is 2-fold: it brings much-needed myopia treatment to children who might not otherwise have access, and it offers students and residents invaluable real-world experience with contact lenses,” said Michele Andrews, OD, vice president of Marketing and Professional Affairs, Americas at CooperVision, in the release. “This experience, which includes hands-on training, helps them prepare to meet the needs of a broader range of patients after graduation.”

New participating centers include Charles River Community Health, The Dimock Center, DotHouse Health, Lynn Community Health Center, Providence Community Health Centers, and South Boston Community Health Center.1

“Programs like Generation Sight are vital in addressing this growing public health concern, particularly in communities where access to eye care is limited. By combining clinical innovation, academic partnerships, and community outreach, CooperVision is creating a scalable model for improving children’s eye health nationwide,” said Andrews in the release.

The initiative offers MiSight 1 day soft contact lenses for age-appropriate children and Paragon CRT orthokeratology lenses at no cost, as long as participating patients require treatment for their myopia.1

Generation Sight was developed in 2024 in partnership with the Illinois College of Optometry, Massachusetts College of Pharmacy and Health Sciences, and New England College of Optometry. The first children were treated through the program in Boston and Chicago in March 2024.2

“The initial group of children enrolled in Generation Sight are pioneers—their experiences and feedback will pave the way for so many others in the months and years ahead,” Andrews said last year in a news release.2

Since then, the program has worked to connect families who would otherwise not have received myopia care with treatment by utilizing collaborations with optometry school faculty, residents, and students.1

References:
  1. CooperVision’s Generation Sight expands reach. News release. CooperVision. June 22, 2025. Accessed June 23, 2025. https://coopervision.com/practitioner/ecp-viewpoints/eyes-coopervision/coopervisions-generation-sight-expands-reach
  2. CooperVision’s “Generation Sight” myopia care initiative enrolls first children. News release. CooperVision. March 18, 2024. Accessed June 2025. https://coopervision.com/our-company/news-center/press-release/coopervision-generation-sight-myopia-care-initiative

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Karl Stonecipher ASCRS 2025
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Eva Kim, MD, shares visual outcomes of EVO implantable collamer lens in patients with low to moderate myopia.
Dr Ashley Wallace Tucker speaks on the Myopia Management Navigator.
Paul Karpecki, OD, FAAO
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
© 2025 MJH Life Sciences

All rights reserved.